SLC26A2

Across TCGA pan-cancer cohorts, SLC26A2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC26A2 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SLC26A2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC26A2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

LSCC, LUAD, and OV are the cancer types where SLC26A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	All	0.599	0.870	.006	15	view →
LUAD	DFS	Tertile	All	0.885	0.973	.022	5	view →
OV	DFS	Median	All	0.856	1.000	.027	4	view →
PDAC	OS	Tertile	II,III,IV	0.577	0.315	.038	4	view →
GBM	DFS	Tertile	All	0.269	0.446	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC26A2–LSCC (DFS)

Open the LSCC breakdown →